Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sailaja Puttagunta

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The Journal of Antimicrobial Chemotherapy|November 1, 2015
Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitisYoav Barnea, Anat Lerner, Asaf Aizic, et al.
Journal of Global Antimicrobial Resistance|February 24, 2019
Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infectionsUrania Rappo, Pedro L Gonzalez, Sailaja Puttagunta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 7, 2022
Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized TrialMichael W Dunne, Steven I Aronin, Anita F Das, et al.
Microbiology Spectrum|February 5, 2025
Characterization of sulopenem antimicrobial activity using <i>in vitro</i> time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolatesJoshua M Maher, Michael D Huband, Jill M Lindley, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 4, 2024
A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infectionsMichael W Dunne, Steven I Aronin, Anita F Das, et al.
Infectious Diseases and Therapy|January 30, 2021
Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical TrialsPedro L Gonzalez, Urania Rappo, Veronica Mas Casullo, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2018
<i>In Vitro</i> Activity of Sulopenem, an Oral Penem, against Urinary Isolates of <i>Escherichia coli</i>James A Karlowsky, Heather J Adam, Melanie R Baxter, et al.
Open Forum Infectious Diseases|January 17, 2019
Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and SafetyUrania Rappo, Sailaja Puttagunta, Vadym Shevchenko, et al.
The Pediatric Infectious Disease Journal|January 7, 2017
Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of AgeDaniel Gonzalez, John S Bradley, Jeffrey Blumer, et al.
Nature Communications|July 2, 2025
Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trialIddo Weiner, Maya Kahan-Hanum, Nufar Buchstab, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The Journal of Antimicrobial Chemotherapy|November 1, 2015
Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitisYoav Barnea, Anat Lerner, Asaf Aizic, et al.
Journal of Global Antimicrobial Resistance|February 24, 2019
Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infectionsUrania Rappo, Pedro L Gonzalez, Sailaja Puttagunta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 7, 2022
Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized TrialMichael W Dunne, Steven I Aronin, Anita F Das, et al.
Microbiology Spectrum|February 5, 2025
Characterization of sulopenem antimicrobial activity using <i>in vitro</i> time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolatesJoshua M Maher, Michael D Huband, Jill M Lindley, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 4, 2024
A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infectionsMichael W Dunne, Steven I Aronin, Anita F Das, et al.
Infectious Diseases and Therapy|January 30, 2021
Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical TrialsPedro L Gonzalez, Urania Rappo, Veronica Mas Casullo, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2018
<i>In Vitro</i> Activity of Sulopenem, an Oral Penem, against Urinary Isolates of <i>Escherichia coli</i>James A Karlowsky, Heather J Adam, Melanie R Baxter, et al.
Open Forum Infectious Diseases|January 17, 2019
Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and SafetyUrania Rappo, Sailaja Puttagunta, Vadym Shevchenko, et al.
The Pediatric Infectious Disease Journal|January 7, 2017
Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of AgeDaniel Gonzalez, John S Bradley, Jeffrey Blumer, et al.
Nature Communications|July 2, 2025
Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trialIddo Weiner, Maya Kahan-Hanum, Nufar Buchstab, et al.
Pageof 4